# IMVT catalysts: Immunovant, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/imvt/catalysts

> Immunovant, Inc. (IMVT) has 15 upcoming catalysts. The next is the imeroprubart topline data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IMVT?

Immunovant, Inc. (IMVT) has 15 upcoming catalysts. The next is the imeroprubart topline data readout, 2027. Press release filed with the SEC (EX-99): "The Company expects to report topline data across potentially registrational trials of IMVT-1402 in Graves' disease (GD) and myasthenia gravis (MG) in calendar year 2027." [Calendar and source filings](https://sec-api.dev/companies/imvt/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001764013-26-000121, https://www.sec.gov/Archives/edgar/data/1764013/000176401326000121/exhibit9912026119.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/companies/imvt/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Immunovant, Inc. |
| Ticker | IMVT (Nasdaq) |
| SEC CIK | 1764013 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/imvt |

## Cash runway

Cash $722.3M as of 2026-09-30; quarterly burn $83.2M; about 26.0 months of runway at that rate (XBRL company facts, accession 0001764013-26-000122).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 30, 2022 | [Batoclimab trial start](https://sec-api.dev/pdufa/batoclimab) | IMVT |  | completed | "In the quarter ended June 30, 2022, we initiated our Phase 3 pivotal trial of batoclimab as a treatment for MG." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm)) |
| December 31, 2022 | [Batoclimab trial start](https://sec-api.dev/pdufa/batoclimab) | IMVT |  | completed | "In the quarter ended December 31, 2022, we initiated a pivotal Phase 2b trial of batoclimab as a treatment for CIDP." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm)) |
| June 30, 2023 | [Imeroprubart trial start](https://sec-api.dev/pdufa/imeroprubart) | IMVT |  | completed | "In the quarter ended June 30, 2023, the FDA cleared our IND application for IMVT-1402 and we initiated a Phase 1 clinical trial in healthy adults in New Zealand after approval of the Clinical Trial Application ("CTA") by the regulatory authority, MEDSAFE." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm)) |
| Dec 2024 | [Imeroprubart trial start](https://sec-api.dev/pdufa/imeroprubart) | IMVT | anti-citrullinated protein autoantibody | completed | "Immunovant, Inc. ("we") initiated a potentially registrational trial evaluating IMVT-1402 in anti-citrullinated protein autoantibody ("ACPA") positive D2T RA in December 2024." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/d760155d8k.htm)) |
| February 6, 2025 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Reports Financial Results for the Quarter Ended December 31, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/exhibit9912025206.htm)) |
| March 31, 2025 | [Imeroprubart trial start](https://sec-api.dev/pdufa/imeroprubart) | IMVT | active, anti-citrullinated protein autoantibody | completed | "For example, we expect our research and development expenses to significantly increase as we seek to execute our plan to initiate four to five potentially registrational programs for IMVT-1402 by March 31, 2025 and initiate trials of IMVT-1402 in ten indications (inclusive of the four to five programs initiated in fiscal 2025) by March 31, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000026/imvt-20241231.htm)) |
| March 31, 2025 | [Batoclimab topline data readout](https://sec-api.dev/pdufa/batoclimab) | IMVT |  | completed, met | "Immunovant intends to report top-line results from the pivotal trial of batoclimab in MG by March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000024/exhibit9912025206.htm)) |
| May 29, 2025 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000091/exhibit9912025529.htm)) |
| Jun 2025 | [Imeroprubart trial start](https://sec-api.dev/pdufa/imeroprubart) | IMVT |  | completed | "•Initiated a second potentially registrational study of IMVT-1402 in Graves' disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren's disease (SjD), both in June 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/exhibit9912025811.htm)) |
| 2H 2025 | [Imeroprubart topline data readout](https://sec-api.dev/pdufa/imeroprubart) | IMVT |  | scheduled | "Multiple near-term milestones for enhanced value creation Jan 2025 TED: Topline results for both trials expected in 2H 2025 MG: Topline Phase 3 results, and CIDP: Initial Phase 2b period 1 data expected by March 31, 20252 1." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000009/exhibit991.htm)) |
| 2H 2025 | [Immunovant, Inc. topline data readout](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | scheduled | "Multiple near-term milestones for enhanced value creation Jan 2025 TED: Topline results for both trials expected in 2H 2025 MG: Topline Phase 3 results, and CIDP: Initial Phase 2b period 1 data expected by March 31, 20252 1." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000009/exhibit991.htm)) |
| 2H 2025 | [Batoclimab topline data readout](https://sec-api.dev/pdufa/batoclimab) | IMVT | thyroid eye disease | scheduled | "Additionally, top-line results for batoclimab from potentially registrational Phase 3 trials in thyroid eye disease are expected in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1846253/000184625325000053/a2025q1ex991.htm)) |
| July 25, 2025 | [Imvt-1401 (batoclimab) primary completion](https://sec-api.dev/pdufa/imvt-1401-batoclimab) | IMVT | Graves Disease | completed | "NCT05907668 (A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05907668)) |
| August 11, 2025 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/exhibit9912025811.htm)) |
| November 2, 2025 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Thyroid Eye Disease | completed | "NCT05517421 (Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-02 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05517421)) |
| November 10, 2025 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000148/exhibit99120251110.htm)) |
| 1H 2026 | [Batoclimab topline data readout](https://sec-api.dev/pdufa/batoclimab) | IMVT |  | scheduled | "However, due to evolving competitive dynamics, we anticipate sharing top-line results from both TED studies concurrently in the first half of calendar year 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/d760155d8k.htm)) |
| February 3, 2026 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Thyroid Eye Disease | completed | "NCT05524571 (Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-03 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05524571)) |
| February 6, 2026 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/exhibit991202626.htm)) |
| Apr 2026 | [Batoclimab topline data readout](https://sec-api.dev/pdufa/batoclimab) | IMVT | active, moderate-to-severe thyroid eye disease | completed, met | "In April 2026, we announced topline results from the two Phase 3 clinical studies evaluating batoclimab for adults with active, moderate-to-severe thyroid eye disease (TED), neither of which met the primary endpoint." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/exhibit9912026520.htm)) |
| April 2, 2026 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Thyroid Eye Disease | withdrawn | "NCT05517447 (Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-04-02 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05517447)) |
| May 20, 2026 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/exhibit9912026520.htm)) |
| 2H 2026 | [Imeroprubart topline data readout](https://sec-api.dev/pdufa/imeroprubart) | IMVT |  | scheduled | "The Company expects to provide further updates on its potentially registrational IMVT-1402 D2T RA program and report topline data from the proof-of-concept trial of IMVT-1402 in CLE in the second half of calendar year 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm)) |
| July 16, 2026 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Chronic Inflammatory Demyelinating Polyneuropathy | withdrawn | "NCT07188844 (An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-16 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07188844)) |
| July 20, 2026 | [Batoclimab 680 milligrams (mg) subcutaneous (sc) weekly primary completion](https://sec-api.dev/pdufa/batoclimab-680-milligrams-mg-subcutaneous-sc-weekly) | IMVT | Chronic Inflammatory Demyelinating Polyneuropathy | withdrawn | "NCT05581199 (To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-20 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05581199)) |
| August 6, 2026 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm)) |
| August 13, 2026 | [Imvt-1401 (batoclimab) topline data readout](https://sec-api.dev/pdufa/imvt-1401-batoclimab) | IMVT | Graves Disease | completed | "NCT05907668 (A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05907668?tab=results)) |
| October 2026 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | delayed | "NCT06980805 (A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06980805)) |
| Oct 2026 to Jan 2027 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | scheduled | "NCT06980805 (A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06980805)) |
| November 9, 2026 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000121/exhibit9912026119.htm)) |
| 2027 | [Imeroprubart topline data readout](https://sec-api.dev/pdufa/imeroprubart) | IMVT | Graves' Disease | scheduled | "The Company expects to report topline data across potentially registrational trials of IMVT-1402 in Graves' disease (GD) and myasthenia gravis (MG) in calendar year 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000121/exhibit9912026119.htm)) |
| May 2027 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT07018323 (A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07018323)) |
| May to Aug 2027 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT07018323 (A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07018323)) |
| September 2027 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Rheumatoid Arthritis | scheduled | "NCT06754462 (A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06754462)) |
| Sep to Dec 2027 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Rheumatoid Arthritis | scheduled | "NCT06754462 (A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06754462)) |
| December 2027 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Generalized Myasthenia Gravis | scheduled | "NCT07039916 (Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07039916)) |
| Dec 2027 to Mar 2028 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Generalized Myasthenia Gravis | scheduled | "NCT07039916 (Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07039916)) |
| June 2028 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT06727604 (A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06727604)) |
| Jun to Sep 2028 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT06727604 (A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06727604)) |
| July 2028 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Primary Sjögren's Syndrome | scheduled | "NCT06979531 (Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979531)) |
| Jul to Oct 2028 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Primary Sjögren's Syndrome | scheduled | "NCT06979531 (Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979531)) |
| August 2028 | [Imeroprubart primary completion](https://sec-api.dev/pdufa/imeroprubart) | IMVT | Chronic Inflammatory Demyelinating Polyneuropathy | scheduled | "NCT07032662 (Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07032662)) |
| Aug to Nov 2028 | [Imeroprubart topline data readout](https://sec-api.dev/pdufa/imeroprubart) | IMVT | Chronic Inflammatory Demyelinating Polyneuropathy | scheduled | "NCT07032662 (Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07032662)) |
| March 2030 | [IMVT-1402 primary completion](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT07286006 (A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286006)) |
| Mar to Jun 2030 | [IMVT-1402 topline data readout](https://sec-api.dev/pdufa/imvt-1402) | IMVT | Graves' Disease | scheduled | "NCT07286006 (A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07286006)) |

## Drugs

- [Batoclimab](https://sec-api.dev/pdufa/batoclimab): active, moderate-to-severe thyroid eye disease, thyroid eye disease, Chronic Inflammatory Demyelinating Polyneuropathy
- [Batoclimab 680 milligrams (mg) subcutaneous (sc) weekly](https://sec-api.dev/pdufa/batoclimab-680-milligrams-mg-subcutaneous-sc-weekly): Chronic Inflammatory Demyelinating Polyneuropathy
- [Imeroprubart](https://sec-api.dev/pdufa/imeroprubart): graves' disease, anti-citrullinated protein autoantibody, active, anti-citrullinated protein autoantibody, Chronic Inflammatory Demyelinating Polyneuropathy
- [Imvt-1401 (batoclimab)](https://sec-api.dev/pdufa/imvt-1401-batoclimab): Graves Disease
- [IMVT-1402](https://sec-api.dev/pdufa/imvt-1402): Graves' Disease, Generalized Myasthenia Gravis, Subacute Cutaneous Lupus Erythematosus, Rheumatoid Arthritis, Primary Sjögren's Syndrome

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/imvt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IMVT catalysts: Immunovant, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/imvt/catalysts

```bibtex
@misc{secapidev_companies_imvt_catalysts_20261116,
  title        = {IMVT catalysts: Immunovant, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/imvt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_imvt_catalysts_20261116","title":"IMVT catalysts: Immunovant, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/imvt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
